BidaskClub upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research report report published on Saturday morning, BidAskClub reports.

Other analysts also recently issued reports about the company. Lake Street Capital initiated coverage on OraSure Technologies in a research report on Thursday, June 25th. They set a buy rating and a $19.00 price objective for the company. ValuEngine downgraded OraSure Technologies from a buy rating to a hold rating in a research report on Friday, May 1st. Stephens initiated coverage on OraSure Technologies in a research report on Tuesday, April 21st. They set an equal weight rating and a $14.00 price objective for the company. Finally, Zacks Investment Research upgraded OraSure Technologies from a hold rating to a strong-buy rating and set a $18.00 price objective for the company in a research report on Wednesday, May 6th. Four research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. OraSure Technologies has a consensus rating of Buy and an average price target of $14.75.

NASDAQ:OSUR opened at $11.63 on Friday. The stock has a fifty day moving average price of $12.60 and a 200-day moving average price of $9.86. The company has a market cap of $674.66 million, a price-to-earnings ratio of 58.15 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.62 and a current ratio of 8.48. OraSure Technologies has a fifty-two week low of $5.23 and a fifty-two week high of $18.27.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $31.60 million for the quarter, compared to the consensus estimate of $29.48 million. OraSure Technologies had a net margin of 8.06% and a return on equity of 1.69%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.05) earnings per share. Research analysts predict that OraSure Technologies will post -0.19 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. American Capital Management Inc. increased its holdings in OraSure Technologies by 0.4% in the 4th quarter. American Capital Management Inc. now owns 3,158,570 shares of the medical instruments supplier’s stock worth $25,363,000 after purchasing an additional 11,532 shares in the last quarter. State Street Corp increased its holdings in OraSure Technologies by 2.7% in the 1st quarter. State Street Corp now owns 2,642,713 shares of the medical instruments supplier’s stock worth $28,436,000 after purchasing an additional 69,817 shares in the last quarter. Bank of America Corp DE increased its holdings in OraSure Technologies by 1,208.5% in the 4th quarter. Bank of America Corp DE now owns 1,106,235 shares of the medical instruments supplier’s stock worth $8,883,000 after purchasing an additional 1,021,692 shares in the last quarter. Geode Capital Management LLC increased its holdings in OraSure Technologies by 6.0% in the 1st quarter. Geode Capital Management LLC now owns 923,604 shares of the medical instruments supplier’s stock worth $9,937,000 after purchasing an additional 52,244 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in OraSure Technologies by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 899,341 shares of the medical instruments supplier’s stock worth $7,222,000 after purchasing an additional 73,619 shares in the last quarter. 90.07% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Read More: How does quantitative easing work?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.